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Macsai have no conflicts of interest to declare. 45 46 47 IRB approval status: N/A 48 and a recent analysis of worldwide epidemiological data estimated that rosacea may affect 5.5 139 percent of the population on a global basis. 3 The disorder is diagnosed more often in women 140 than men, and onset typically occurs after age 30, though it may develop at any age. The density 141
of Demodex mites is often found at higher levels in rosacea patients than in those without the 142 disorder. 4 
143
Rosacea's unsightly and conspicuous appearance often has significant emotional 144 ramifications, potentially resulting in depression or anxiety, and frequently interferes with social 145 and occupational interactions. 5-14 146
Ocular manifestations occur in more than 50 percent of those with rosacea, and may 147 appear before or in the absence of cutaneous features. 15 Symptoms may include dryness, 148 burning and stinging, light sensitivity, blurred vision, and foreign body sensation. External, 149 readily apparent signs include lid margin and conjunctival telangiectases, plugging of the 150 meibomian glands, and chalazia. In advanced disease patients may present with chalazion 151 affecting the eyelid. Severe ocular rosacea may lead to corneal inflammation and scarring and, 152 conceivably, corneal perforation, with loss of visual acuity. 16 153
Although causal relationships have not been determined, recent studies have found an 154 association between rosacea and increased risk of a growing number of systemic disorders, 155 including cardiovascular, gastrointestinal, neurological, and autoimmune diseases, as well as 156 certain types of cancer. These findings further elevate the clinical significance of rosacea as 157 growing evidence of its potential link with systemic inflammation is increasingly understood, 17-158 32 though in many disorders there may be either conflicting study results or there is only one 159 study to suggestion the association. In practice, the subtype designations were widely interpreted as distinct entities, which 169 tended to limit consideration of the full range of potential signs and symptoms as well as the 170 frequent simultaneous occurrence of more than one subtype or the potential progression from 171 one subtype to another. In addition, subsequent research uncovered important new insights into 172 rosacea's pathogenesis and pathophysiology, and suggest that a consistent multivariate disease 173 process underlies the various clinical manifestations of the disorder. 174
To fulfill the directive of the original authors, a committee and review panel of 28 175 experts was convened by the NRS to develop an updated standard classification system, 176 published in the Journal of the American Academy of Dermatology in 2018. 1 Based on 177 phenotypes to reflect current knowledge of its pathophysiology, the new standard classification 178 of rosacea provides a means of assessing rosacea so that therapy can be personalized in a 179 manner consistent with each patient's individual experience. 180
As a further step, the committee has now developed recommended management options 181 for rosacea based on these standard criteria to assist in providing optimal patient care. Because it 182 is fundamental to consider the broad spectrum of potential therapies in the treatment of rosacea, 183 the consensus committee and review panel have been broadened to include 27 clinical experts in 184 dermatology, laser therapy, skin care, and ophthalmology. 185
The committee reviewed the relevant literature and met to discuss the extent of evidence 186 as well as the level of efficacy of various therapies. The discussion was captured via audio 187 recording, and a first draft was prepared with input from all participants. The draft was then 188 reviewed and edited by all committee members, and was finalized only after all assessments 189 were unanimously approved. The document was then further reviewed by the panel of 190 additional rosacea experts, and virtually all edits and comments were accepted by the 191
committee. 192
As with the updated standard classification system, the proposed standard management 193 options are considered provisional and may be updated as scientific knowledge increases and 194 additional therapies become available. 195 196
Diagnosis and assessment 197
There is no definitive laboratory test for rosacea, and diagnosis is based on clinical 198 observation as well as a patient history, which can be essential as some features may not be 199 visually evident or present at the time of the patient visit. Features identified in the new standard 200 classification system are listed in Table I , including diagnostic, major, and secondary (minor). 1 
201
When assessing treatment, the committee noted that patients' perception and acceptance 202 of their facial appearance -including its impact on their emotional, social, and professional 203 lives -may be important in determining the level of therapy. Patient surveys have suggested 204 that the psychosocial burden of rosacea may be substantial regardless of severity, [4] [5] [6] and the goal 205 of achieving an investigator global assessment (IGA) of 0 for inflammatory papules and 206 pustules may often be appropriate and feasible. 35 It may also be advisable to remind patients that 207 normalization of skin tone and color is the goal rather than complete eradication of facial 208 coloration, which can leave the face with a sallow appearance. 209 210
Management options 211
Although there is no cure for rosacea, its features may be reduced or controlled with a 212 range of topical and oral therapies and light devices, as well as appropriate skin care and 213 lifestyle management. Combination therapy to target the specific features of each rosacea 214 patient is often necessary for effective treatment. The treatments listed in Tables II-IV are  215 intended to serve as a menu of options rather than a treatment protocol. 216
While data is limited on the efficacy of many medical therapies, recent systematic 217 evaluations have also found variability in the quality of evidence. 36, 37 Patients and features of 218 the disease may respond well or less well to various agents, and when treatments are effective, 219 the mechanism(s) of action may be unclear. Consequently, the Tables represent the committee' research has found that all appear to be manifestations of the same underlying inflammatory 226 continuum. 1 Therefore, any particular therapy may prove to be acting on an aspect of that 227 continuum. Recent studies point to a multivariate set of pathogenic pathways, including defects 228 in the innate and adaptive immune systems, mast cells and related biochemical mechanisms, and 229 the neurovascular system. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] The phenotype approach may also result in the discovery of 230 biomarkers and the development of more precise measuring systems. 231 232
Drugs 233
The FDA-approved topical therapies for inflammatory papules/pustules of rosacea 234 include azelaic acid, 15%; ivermectin cream, 1%; metronidazole 1% and 0.75%; and sodium 235 sulfacetamide 10% in various formulations. Modified release oral doxycycline capsules, 40 mg 236 (30 mg immediate release and 10 mg delayed release beads), were approved by the FDA for the 237 treatment of inflammatory papules/pustules of rosacea with a lower dosage than that of 238 doxycycline used to treat infections, and have been associated with fewer side effects and 239
shown to be safe for long-term use. The use of this agent has not been associated with the 240 development of bacterial resistance. 55 Topical and oral therapy are often initially prescribed in 241 combination, followed by long-term use of a single therapy alone to maintain remission. 56-59 242
When first-line treatments for inflammation are inadequate or when rosacea is more 243 severe, off-label oral antibiotics or retinoids are sometimes used, though there is little data. 244
These may include tetracycline, doxycycline, minocycline, and oral isotretinoin. Prevention of 245 pregnancy during treatment with the latter is crucial, and management includes routine 246 pregnancy tests and adherence to pregnancy prevention protocols. Tetracycline should also be 247 avoided in pregnancy as fetal and maternal toxicity have been reported and use during tooth 248 development may cause tooth discoloration. 249
The FDA-approved topical therapies for the treatment of persistent facial erythema of 250 rosacea in adults include brimonidine topical gel, 0.33%, an alpha-adrenergic agonist, and 251 oxymetazoline hydrochloride cream, 1%, an alpha 1A adrenoceptor agonist. 252
Off-label use of various drugs has sometimes been prescribed to help control flushing, 253
including nonsteroidal anti-inflammatory drugs, antihistamines, clonidine, and beta-blockers. 254 255
Light devices 256
Though the quality of clinical evidence is limited, two types of laser, pulsed-dye and 257 potassium titanyl phosphate (KTP), are well established in practice and have been shown to be 258 highly effective in removing telangiectasia and diminishing erythema. 60 decrease the presence of bacteria and to soften any collarettes, allowing easy removal by the 278 patient during eyelash hygiene. Topical cyclosporine drops may be additive in decreasing the 279 topical inflammation in these patients. An oral tetracycline such as modified release, 280 subantimicrobial doxycycline may also be used. 66 In recent studies topical azithromycin has 281 been demonstrated to be equally as effective as oral doxycycline, with fewer side effects in the 282 treatment of the ocular manifestations of rosacea. [67] [68] [69] [70] [71] For severe ocular rosacea other oral 283 medications may be prescribed by an ophthalmologist. Any corneal ulceration, inflammation, or 284 red eye should be immediately referred to an ophthalmologist, as it may result in reduced visual 285
acuity. 286
In experienced hands, IPL for cutaneous rosacea phenotypes has been found to elicit 287 improvement in ocular rosacea signs and symptoms as well, suggesting a field effect. [72] [73] [74] [75] [76] In 288 addition, effective devices are available that improve inspissated meibum using thermopulsation 289 that decreases symptoms of irritation. 77-79 290 291 factors that appear to affect their rosacea in order to help identify and avoid their personal 299 triggers. Surveys have found the most common factors to be sun exposure, emotional stress, hot 300 weather, wind, heavy exercise, alcohol consumption, hot baths, cold weather, spicy foods, 301 humidity, indoor heat, certain skin-care products, heated beverages, certain medications, 302 medical conditions, certain fruits, marinated meats, certain vegetables, and dairy products. 80 303
Lifestyle management 292
As the disorder's unsightly appearance and unpredictability of flares often negatively 304 affect the social and occupational aspects of patients' lives, this in turn may become a source of 305 stress that can trigger further exacerbation in an adverse and self-propagating spiral. 6-14 306 307 308
Skin care 309
Gentle skin care is an important component of rosacea management, as patients with 310 rosacea often have skin that is sensitive and easily irritated, causing redness, burning, and 311 stinging. Thus the goal of daily skin care for rosacea patients is to maintain the integrity of the 312 skin barrier while avoiding agents that aggravate inflammation or flushing. 313
As sun exposure may be a leading influence on the development of flushing and 314 erythema, patients are advised to always use sunscreens, preferably mineral inorganic products 315 that contain zinc oxide or titanium dioxide, because they do not produce heat as a byproduct and 316 provide physical rather than potentially irritating chemical protection. Mineral-based sunscreens 317 primarily reflect and secondarily absorb UV radiation as zinc oxide and titanium dioxide are 318 coated with silicone to prevent the generation of secondary oxygen radicals resulting from UV 319 absorption, although one recent study suggests absorption may be the primary mechanism of 320 protection. 81 There are also options, which include micronized, nanoparticle, and clear 321 formulations, for rosacea sufferers with darker skin, as past formulations left a chalky white or 322 grayish appearance. 323
There is a plethora of mass-market over-the-counter topical skin care products that claim 324 to soothe the skin and reduce the appearance of redness. Though there is sparse data to validate 325 the claims, such products will typically contain one of the following nonprescription 326 ingredients: sunscreen, sulfur, and botanical substances including allantoin, bisabolol (a 327 chamomile-derived extract), licorice root extracts (with licochalcones as the active agent), 328 willowbark (active agent, a salicylate), or aloe vera (active agent a salicylate and alloemodin). 329
While forms of sulfur and botanical ingredients may potentially account for a degree of anti-330 inflammatory effect, published clinical studies for the treatment of specific disease are generally 331 not available. 332
As with other skin care products, patients may be advised to select cleansers and 333 nonocclusive moisturizers that do not irritate their skin. 81 Patients should be directed to a gentle 334 cleansing regimen, using a syndet (synthetic detergent) or nonirritating cleanser, washing the 335 face gently, and waiting for the face to completely dry before applying topical therapy or other 336 products, as stinging is more likely to occur when the skin is wet. Cosmetics, especially those 337 with a green or yellow tint, may be effective in reducing the appearance of redness. However, as 338 with cleansers and moisturizers, care should be taken to minimize irritation, and patients should 339 be advised to avoid any products that cause burning, stinging, itching, or other discomfort. 340
341

Conclusion 342
The explosion of rosacea research over the past 15 years has led to a dramatic increase in 343 our understanding of this disorder affecting all skin types that is now beginning to produce 344 significant improvements in the physical health and quality of life for rosacea patients as 345 advances in therapy continue. It now appears that rosacea is caused by a multivariate process 346 and is a disorder whose wide range of features are manifestations of the same underlying 347 inflammation, offering the potential for more precise assessment and treatment of individual 348 patients as well as newly identified inflammatory pathways for the development of new 349 therapies. The new phenotype-based standard classification and management of rosacea provide 350 important insights and guidance for the selection of treatments and broad spectrum of care to 351 achieve optimal patient outcomes. 
